| Kyong Min SHIN Patent applications |
| Patent application number | Title | Published |
|---|
| 20110071514 | METHOD AND SYSTEM FOR CONTROLLING RADIO FREQUENCY OUTPUT ACCORDING TO CHANGE IN IMPEDANCE OF BIOLOGICAL CELLS - Disclosed herein is a method and system for controlling radio frequency (RF) output according to the change in impedance of biological cells. In the method of controlling radio frequency (RF) output according to a change in impedance of biological cells, phases of RF voltage and current applied to the electrode are detected and a difference between the phases is obtained. A change in impedance such as a resistance component and a capacitive reactance component (XC) of the biological cells at the time of performing cauterization is obtained. An inductive reactance component (XL) is connected to an RF output terminal so as to cancel the capacitive reactance component (XC) (XC=XL), thus enabling the output impedance to have a resistance component. | 03-24-2011 |
| 20110071513 | COMMON-MODE NOISE FILTER OF RADIO FREQUENCY GENERATOR FOR RADIOFREQUENCY ABLATION - Disclosed herein is a common-mode noise filter of an RF generator for radiofrequency ablation. The common-mode noise filter of the RF generator for RFA amplifies an oscillation frequency provided by an oscillator to AC output using amplification means, and providing the amplified oscillation frequency to electrodes. The common-mode noise filter is disposed between the amplification means and the electrodes, thus eliminating harmonic components generated by the electrodes depending on conditions of medical treatment when the electrodes are used. Accordingly, the present invention can prevent the distortion of images or waveforms attributable to harmonic components from occurring in a diagnostic imaging device such as a diagnostic ultrasound system used together with the RF generator for RFA as well as in the RF generator's own display unit. | 03-24-2011 |
| 20110069518 | RESONANT INVERTER OF RADIO FREQUENCY GENERATOR FOR RADIOFREQUENCY ABLATION - Disclosed herein is the resonant inverter of a radio frequency (RF) generator for radiofrequency ablation (RFA). The resonant inverter of RF generator for RFA amplifies to high power an oscillation frequency output from an oscillator and provides the amplified oscillation frequency to an electrode. The resonant inverter processes the oscillation frequency output from the oscillator as a high-power sine wave having a frequency of 480 kHz and a Root Mean Square (RMS) power of 30 to 200 watts, and transfers the high-power sine wave to the electrode. | 03-24-2011 |
| 20110022151 | STENT - If smooth transportation of bile toward the duodenum is difficult due to cancerous cells growing in the bile duct or due to stricture of the bile duct, a cylindrical stent may be implanted into the stenosed site of the bile duct to enable smooth supply of bile. Conventional stents have no risk of slippage at an implanted position thereof, but suffer from invasively growing cancerous cells. Although a covered stent having a coating has been proposed to solve invasion of the growing cancerous cells, the covered stent may have a risk of slippage at an implanted position thereof and also, may cause pancreatitis and cholelithiasis. To solve the above described problems, disclosed herein is a stent to prevent backflow of food from the duodenum to the bile duct while assuring smooth transportation of bile without a risk of unwanted displacement caused by the transported bile. The stent includes a cylindrical outer stent, and a downwardly tapered inner stent covered with a polytetrafluoroethylene (PTFE) or silicone coating having biocompatibility. The inner and outer stents are coupled to each other to define a double structure. | 01-27-2011 |
| 20090286864 | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith - Disclosed are a coating agent for drug releasing stents, a method for preparing the same and a drug releasing stent coated therewith. The coating agent for drug releasing stents comprises nanoparticles with a biologically active material entrapped therein, wherein the particles are formed of a polyethyleneimine (PEI)-deoxycholic acid (DOCA) polymer (PDo) in which 1˜8 moles of DOCA are grafted per mole of PEI. | 11-19-2009 |
| 20090192627 | DOUBLE-TUBE TYPE STENT - A double-tube type stent is inserted into a hollow tubular organ such as a bile duct so as to relieve narrowing of the bile duct on, for instance, an anastomotic area of the intrahepatic bile duct of a liver transplant patient. A hollow cylindrical body has a plurality of rhombic spaces formed by weaving a superelastic shape-memory-alloy wire so as to be crossed. A silicon coating layer is coated on an outer surface of the cylindrical body using a silicon solution. A polytetrafluoroethylene (PTFE) tube is fixedly fitted around the cylindrical body having the silicon coating layer leaving a gap therebetween. | 07-30-2009 |
| 20090192588 | BIODEGRADABLE DOUBLE STENT - A biodegradable double stent is used for various organs such as a biliary tract, an esophagus, an airway and a ureter. A biodegradable stent having a hollow cylindrical body woven out of a separate wire made of biodegradable polymer so as to have a plurality of rhombic spaces is fixed to an intermediate portion of a primary stent having a cylindrical body. When administered into the organ, the biodegradable stent has its original function of expanding the organ, and is firmly supported in the inner wall of a narrowed passage of the organ by pressurizing the inner wall of the narrowed passage of the organ. After a predetermined time period has elapsed, the biodegradable stent is gradually degraded away by bodily fluids, thereby enabling the primary stent to be easily removed from the organ. | 07-30-2009 |
| 20080300296 | Coating agent for drug releasing stent, preparation method thereof and drug releasing stent coated therewith - Disclosed are a coating agent for drug releasing stents, a method for preparing the same and a drug releasing stent coated therewith. The coating agent comprises a biologically active material and a coating material selected from among pullulan acetate, represented by the following Chemical Formula 1, and a polyurethane-surfactant mixture. | 12-04-2008 |
